© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.
October 8th 2021
John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).
Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.
October 15th 2021
Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.
Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.
October 22nd 2021
John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.
John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.
October 29th 2021
Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.
Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.
November 5th 2021
Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.
Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.